# Maintenance olaparib for patients with newly diagnosed advanced ovarian cancer and a BRCA mutation (SOLO1/GOG 3004): 5-year follow-up of a randomised, double-blind, placebo-controlled, phase 3 trial

**Type:** Papers  
**Canonical URL:** https://scholariq.org/papers/maintenance-olaparib-for-patients-with-newly-diagnosed-advanced-ovarian-cancer/

## Facts

| Field | Value |
| --- | --- |
| Author Names | Susana Banerjee,Kathleen N Moore,Nicoletta Colombo,Giovanni Scambia,Byoung-Gie Kim,Ana Oaknin,Michael Friedlander,Alla Lisyanskaya,Anne Floquet,Alexandra Leary,Gabe S Sonke,Charlie Gourley,Amit Oza,Antonio González-Martín,Carol Aghajanian,William H Bradley,Eileen Holmes,Elizabeth S Lowe,Paul DiSilvestro |
| Citations | 379 |
| DOI | 10.1016/s1470-2045(21)00531-3 |
| Fields | Biochemistry, Genetics and Molecular Biology,Medicine |
| Open Access | true |
| OA Status | green |
| OA URL | https://hdl.handle.net/20.500.11820/bd1ea528-5b93-4f38-89a1-f3a21e65cfdd |
| OpenAlex ID | https://openalex.org/W3208204329 |
| PMID | 34715071 |
| Type | article |
| Year | 2021 |

## Paper funders

- [AstraZeneca](https://scholariq.org/funders/astrazeneca/)
- [Merck Sharp and Dohme](https://scholariq.org/funders/merck-sharp-and-dohme/)

## Paper journal

- [The Lancet Oncology](https://scholariq.org/journals/the-lancet-oncology/)

## Paper primary topic

- [PARP inhibition in cancer therapy](https://scholariq.org/topics/parp-inhibition-in-cancer-therapy/)

## Paper topics

- [PARP inhibition in cancer therapy](https://scholariq.org/topics/parp-inhibition-in-cancer-therapy/)
- [Ovarian cancer diagnosis and treatment](https://scholariq.org/topics/ovarian-cancer-diagnosis-and-treatment/)
- [BRCA gene mutations in cancer](https://scholariq.org/topics/brca-gene-mutations-in-cancer/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.